<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40933009</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2604-7276</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>REC, interventional cardiology</Title><ISOAbbreviation>REC Interv Cardiol</ISOAbbreviation></Journal><ArticleTitle>Efficacy of ultrasound renal denervation reducing blood pressure: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>154</StartPage><EndPage>163</EndPage><MedlinePgn>154-163</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/RECICE.M25000509</ELocationID><Abstract><AbstractText Label="INTRODUCTION AND OBJECTIVES" NlmCategory="UNASSIGNED">Ultrasound renal denervation (uRDN) has emerged as an innovative therapeutic approach for the treatment of hypertension. However, its efficacy compared to medication remains uncertain. We aimed to assess the efficacy profile of uRDN vs sham groups focusing on its impact on daytime ambulatory blood pressure, 24-hour blood pressure, home blood pressure and office blood pressure.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a systematic search across Embase, PubMed, and Cochrane Library databases from their inception up 1 November 2024 to identify randomized controlled trials evaluating the efficacy of uRDN. Statistical analyses were performed using RevMan 6.3 software, utilizing the mean and standard deviation method to calculate mean differences with a 95% confidence interval (95%CI).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 4 studies were included in the final analysis with 642 patients. uRDN significantly reduced daytime ambulatory systolic blood pressure (SBP) (-5.12 mmHg; 95%CI, -6.07 to -4.16; P &#x2264; .00001), 24-h SBP (-4.87 mmHg; 95%CI, -6.53 to -3.21]; P &#x2264; .00001), office SBP (-5.03 mmHg; 95%CI, -6.27 to -3.79; P &#x2264; .00001) and showed a decrease in patient medication 6 months after the procedure.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Using uRDN leads to a lower blood pressure in patients within 2 months following the procedure. Additionally, after 6 months a significant decrease in drug use is observed.This meta-analysis protocol was registered on PROSPERO on 7 July 2024 (CRD42024562852).</AbstractText><CopyrightInformation>Copyright: &#xa9; 2025 Sociedad Espa&#xf1;ola de Cardiolog&#xed;a.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guerrero-Hern&#xe1;ndez</LastName><ForeName>Juan Miguel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitario Cl&#xed;nico San Carlos, Madrid, Espa&#xf1;a Servicio de Cardiolog&#xed;a Hospital Universitario Cl&#xed;nico San Carlos Madrid Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palomino-Ojeda</LastName><ForeName>Cristian Jes&#xfa;s</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Facultad de Ciencias de la Salud "Dr. Enrique Ortega Moreira-, Universidad Esp&#xed;ritu Santo, Samborond&#xf3;n, Ecuador Facultad de Ciencias de la Salud "Dr. Enrique Ortega Moreira- Universidad Esp&#xed;ritu Santo Samborond&#xf3;n Ecuador.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Mena</LastName><ForeName>Lissette Haydee</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Departamento de Salud Digital, Facultad de Medicina, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Ciudad de M&#xe9;xico, M&#xe9;xico Departamento de Salud Digital Facultad de Medicina Universidad Nacional Aut&#xf3;noma de M&#xe9;xico Ciudad de M&#xe9;xico M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital General Regional con Medicina Familiar No. 1 "Lic Ignacio Garc&#xed;a T&#xe9;llez-, Instituto Mexicano del Seguro Social, Cuernavaca, Morelos, M&#xe9;xico Hospital General Regional con Medicina Familiar No. 1 "Lic Ignacio Garc&#xed;a T&#xe9;llez- Instituto Mexicano del Seguro Social Cuernavaca M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maldonado-Garc&#xed;a</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Departamento de Bioqu&#xed;mica, Facultad de Medicina, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Ciudad de M&#xe9;xico, M&#xe9;xico Departamento de Bioqu&#xed;mica Facultad de Medicina Universidad Nacional Aut&#xf3;noma de M&#xe9;xico Ciudad de M&#xe9;xico M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vedia-Cruz</LastName><ForeName>&#xd3;scar &#xc1;ngel</ForeName><Initials>&#xd3;&#xc1;</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitario Cl&#xed;nico San Carlos, Madrid, Espa&#xf1;a Servicio de Cardiolog&#xed;a Hospital Universitario Cl&#xed;nico San Carlos Madrid Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Donaire</LastName><ForeName>Jos&#xe9; Antonio</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitario Cl&#xed;nico San Carlos, Madrid, Espa&#xf1;a Servicio de Cardiolog&#xed;a Hospital Universitario Cl&#xed;nico San Carlos Madrid Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N&#xfa;&#xf1;ez-Gil</LastName><ForeName>Iv&#xe1;n Javier</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitario Cl&#xed;nico San Carlos, Madrid, Espa&#xf1;a Servicio de Cardiolog&#xed;a Hospital Universitario Cl&#xed;nico San Carlos Madrid Espa&#xf1;a.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Ciencias Biom&#xe9;dicas de Salud, Universidad Europea de Madrid, Campus de Villaviciosa de Od&#xf3;n, Villaviciosa de Od&#xf3;n, Madrid, Espa&#xf1;a Facultad de Ciencias Biom&#xe9;dicas de Salud Universidad Europea de Madrid Campus de Villaviciosa de Od&#xf3;n Villaviciosa de Od&#xf3;n Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>REC Interv Cardiol</MedlineTA><NlmUniqueID>9919033203206676</NlmUniqueID><ISSNLinking>2604-7306</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="INTRODUCCI&#xd3;N Y OBJETIVOS" NlmCategory="UNASSIGNED">La denervaci&#xf3;n renal por ultrasonido (DRU) ha surgido como un enfoque terap&#xe9;utico innovador para la hipertensi&#xf3;n arterial resistente. Sin embargo, su eficacia en comparaci&#xf3;n con la medicaci&#xf3;n sigue siendo incierta. Nuestro objetivo fue evaluar la eficacia de la DRU frente a grupos simulados, con especial atenci&#xf3;n a su impacto sobre la presi&#xf3;n arterial ambulatoria diurna, la presi&#xf3;n arterial de 24 h, la presi&#xf3;n arterial domiciliaria y la presi&#xf3;n arterial en el consultorio.</AbstractText><AbstractText Label="M&#xc9;TODOS" NlmCategory="UNASSIGNED">Se realiz&#xf3; una b&#xfa;squeda sistem&#xe1;tica en las bases de datos Embase, PubMed y Cochrane Library hasta el 1 de noviembre de 2024, para identificar ensayos controlados aleatorizados que evaluaran la efectividad de la DRU. Los an&#xe1;lisis estad&#xed;sticos se realizaron con el programa inform&#xe1;tico RevMan 6.3, utilizando la media y la desviaci&#xf3;n est&#xe1;ndar para calcular las diferencias de medias con un intervalo de confianza del 95% (IC95%).</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="UNASSIGNED">En el an&#xe1;lisis final se incluyeron cuatro estudios con 642 pacientes. La DRU redujo de manera significativa la presi&#xf3;n arterial sist&#xf3;lica (PAS) ambulatoria diurna (&#x2212;5,12 mmHg; IC95%, &#x2212;6,07 a &#x2212;4,16; p &#x2264; 0,00001), la PAS de 24 h (&#x2212;4,87 mmHg; IC95%, &#x2212;6,53 a &#x2212;3,21; p &#x2264; 0,00001) y la PAS en la consulta (&#x2212;5,03 mmHg; IC95%, &#x2212;6,27 a &#x2212;3,79; p &#x2264; 0,00001), y logr&#xf3; una disminuci&#xf3;n de la medicaci&#xf3;n de los pacientes a los 6 meses del procedimiento.</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="UNASSIGNED">El uso de DRU conlleva una reducci&#xf3;n de la presi&#xf3;n arterial a los 2 meses del procedimiento. Adicionalmente, transcurridos 6 meses se observ&#xf3; una disminuci&#xf3;n significativa del uso de medicaci&#xf3;n.El protocolo de este metan&#xe1;lisis fue registrado en PROSPERO el 7 de julio de 2024 (CRD42024562852).</AbstractText><CopyrightInformation>Copyright: &#xa9; 2025 Sociedad Espa&#xf1;ola de Cardiolog&#xed;a.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antihypertensive</Keyword><Keyword MajorTopicYN="N">Diastolic blood pressure</Keyword><Keyword MajorTopicYN="N">Resistant hypertension</Keyword><Keyword MajorTopicYN="N">Systolic blood pressure</Keyword><Keyword MajorTopicYN="N">Ultrasound renal denervation</Keyword><Keyword MajorTopicYN="N">treatments</Keyword></KeywordList><CoiStatement>CONFLICTO DE INTERESES: I.J. N&#xfa;&#xf1;ez-Gil ha sido consultor de Medtronic y Recor Medical en el campo de la denervaci&#xf3;n. J.A. Garc&#xed;a-Donaire, por su parte, ha sido consultor de Medtronic y Recor Medical, tambi&#xe9;n, en el campo de la denervaci&#xf3;n. Los dem&#xe1;s autores no declararon ning&#xfa;n conflicto de intereses.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40933009</ArticleId><ArticleId IdType="pmc">PMC12418244</ArticleId><ArticleId IdType="doi">10.24875/RECICE.M25000509</ArticleId><ArticleId IdType="pii">2604-7306-recic-7-3-154</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adler A, Agodoa L, Algra A, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure:an individual participant-level data meta-analysis. <i>The Lancet</i>. 2021;39:1625-1636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8102467</ArticleId><ArticleId IdType="pubmed">33933205</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler A, Agodoa L, Algra A, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure:an individual participant-level data meta-analysis. The Lancet. 2021;39:1625&#x2013;1636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8102467</ArticleId><ArticleId IdType="pubmed">33933205</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death:A systematic review and meta-analysis. <i>The Lancet</i>. 2016;387:957-967.</Citation><ArticleIdList><ArticleId IdType="pubmed">26724178</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death:A systematic review and meta-analysis. The Lancet. 2016;387:957&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">26724178</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey RM, Muntner P, Bosworth HB, Whelton PK. Prevention and Control of Hypertension:JACC Health Promotion Series. <i>J Am Coll Cardiol</i>. 2018;72:1278-1293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6481176</ArticleId><ArticleId IdType="pubmed">30190007</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey RM, Muntner P, Bosworth HB, Whelton PK. Prevention and Control of Hypertension: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72:1278&#x2013;1293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6481176</ArticleId><ArticleId IdType="pubmed">30190007</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication adherence and blood pressure control:A scientific statement from the american heart association. <i>Hypertension</i>. 2022;79:E1-E14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11485247</ArticleId><ArticleId IdType="pubmed">34615363</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication adherence and blood pressure control:A scientific statement from the american heart association. Hypertension. 2022;79:E1&#x2013;E14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11485247</ArticleId><ArticleId IdType="pubmed">34615363</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan BM, Zhao Y, Li J, et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. <i>Hypertension</i>. 2013;62:691-697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066303</ArticleId><ArticleId IdType="pubmed">23918752</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan BM, Zhao Y, Li J, et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013;62:691&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066303</ArticleId><ArticleId IdType="pubmed">23918752</ArticleId></ArticleIdList></Reference><Reference><Citation>Flack JM, Buhnerkempe MG, Moore KT. Resistant Hypertension:Disease Burden and Emerging Treatment Options. <i>Curr Hypertens Rep</i>. 2024;26:183-199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11533979</ArticleId><ArticleId IdType="pubmed">38363454</ArticleId></ArticleIdList></Reference><Reference><Citation>Flack JM, Buhnerkempe MG, Moore KT. Resistant Hypertension:Disease Burden and Emerging Treatment Options. Curr Hypertens Rep. 2024;26:183&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11533979</ArticleId><ArticleId IdType="pubmed">38363454</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassi G, Ram VS. Evidence for a critical role of the sympathetic nervous system in hypertension. <i>J Am Soc Hypertens</i>. 2016;10:457-466.</Citation><ArticleIdList><ArticleId IdType="pubmed">27052349</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassi G, Ram VS. Evidence for a critical role of the sympathetic nervous system in hypertension. J Am Soc Hypertens. 2016;10:457&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">27052349</ArticleId></ArticleIdList></Reference><Reference><Citation>Mabin T, Sapoval M, Cabane V, Stemmett J, Iyer M. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. <i>EuroIntervention</i>. 2012;8:57-61.</Citation><ArticleIdList><ArticleId IdType="pubmed">22580249</ArticleId></ArticleIdList></Reference><Reference><Citation>Mabin T, Sapoval M, Cabane V, Stemmett J, Iyer M. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. EuroIntervention. 2012;8:57&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">22580249</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasgupta I, Sharp ASP. Renal sympathetic denervation for treatment of hypertension:where are we now in 2019?<i>Curr Opin Nephrol Hypertens</i>. 2019;28:498-506.</Citation><ArticleIdList><ArticleId IdType="pubmed">31268917</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasgupta I, Sharp ASP. Renal sympathetic denervation for treatment of hypertension:where are we now in 2019? Curr Opin Nephrol Hypertens. 2019;28:498&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">31268917</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbato E, Azizi M, Schmieder RE, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>Eur Heart J</i>. 2023;44:1313-1330.</Citation><ArticleIdList><ArticleId IdType="pubmed">36790101</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbato E, Azizi M, Schmieder RE, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J. 2023;44:1313&#x2013;1330.</Citation><ArticleIdList><ArticleId IdType="pubmed">36790101</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Leor O, Ja&#xe9;n-&#xc1;guila F, Segura J, et al. Renal denervation for the management of hypertension. Joint position statement from the SEH-LELHA and the ACI-SEC. <i>REC Interv Cardiol. 2022;4:39-46</i>.</Citation></Reference><Reference><Citation>Rodr&#xed;guez-Leor O, Ja&#xe9;n-&#xc1;guila F, Segura J, et al. Renal denervation for the management of hypertension. Joint position statement from the SEH-LELHA and the ACI-SEC. REC Interv Cardiol. 2022;4:39&#x2013;46.</Citation></Reference><Reference><Citation>Schmieder R, Burnier M, East C, Tsioufis K, Delaney S. Renal Denervation:A Practical Guide for Health Professionals Managing Hypertension. <i>Interv Cardiol</i>. 2023;18:e06.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10433107</ArticleId><ArticleId IdType="pubmed">37601735</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmieder R, Burnier M, East C, Tsioufis K, Delaney S. Renal Denervation:A Practical Guide for Health Professionals Managing Hypertension. Interv Cardiol. 2023;18:e06.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10433107</ArticleId><ArticleId IdType="pubmed">37601735</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN):a multicentre, open-label, randomised controlled trial. <i>Lancet</i>. 2015;385:1957-1965.</Citation><ArticleIdList><ArticleId IdType="pubmed">25631070</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN):a multicentre, open-label, randomised controlled trial. Lancet. 2015;385:1957&#x2013;1965.</Citation><ArticleIdList><ArticleId IdType="pubmed">25631070</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt DL, Kandzari DE, O'Neill WW, et al. A Controlled Trial of Renal Denervation for Resistant Hypertension. <i>N Engl J Med.</i> 2014;370:1393-1401.</Citation><ArticleIdList><ArticleId IdType="pubmed">24678939</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt DL, Kandzari DE, O'Neill WW, et al. A Controlled Trial of Renal Denervation for Resistant Hypertension. N Engl J Med. 2014;370:1393&#x2013;1401.</Citation><ArticleIdList><ArticleId IdType="pubmed">24678939</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiermaier T, Okon T, Fengler K, et al. Endovascular ultrasound for renal sympathetic denervation in patients with therapy-resistant hypertension not responding to radiofrequency renal sympathetic denervation. <i>EuroIntervention</i>. 2016;12:e282-e289.</Citation><ArticleIdList><ArticleId IdType="pubmed">27290688</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiermaier T, Okon T, Fengler K, et al. Endovascular ultrasound for renal sympathetic denervation in patients with therapy-resistant hypertension not responding to radiofrequency renal sympathetic denervation. EuroIntervention. 2016;12:e282&#x2013;e289.</Citation><ArticleIdList><ArticleId IdType="pubmed">27290688</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO):a multicentre, international, single-blind, randomised, sham-controlled trial. <i>Lancet</i>. 2018;391:2335-2345.</Citation><ArticleIdList><ArticleId IdType="pubmed">29803590</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO):a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391:2335&#x2013;2345.</Citation><ArticleIdList><ArticleId IdType="pubmed">29803590</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizi M, Sanghvi K, Saxena M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO):a randomised, multicentre, single-blind, sham-controlled trial. <i>Lancet</i>. 2021;397:2476-2486.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010611</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizi M, Sanghvi K, Saxena M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO):a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397:2476&#x2013;2486.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010611</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizi M, Saxena M, Wang Y, et al. Endovascular Ultrasound Renal Denervation to Treat Hypertension:The RADIANCE II Randomized Clinical Trial. <i>JAMA</i>. 2023;329(8):651-661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9975904</ArticleId><ArticleId IdType="pubmed">36853250</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizi M, Saxena M, Wang Y, et al. Endovascular Ultrasound Renal Denervation to Treat Hypertension:The RADIANCE II Randomized Clinical Trial. JAMA. 2023;329(8):651&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9975904</ArticleId><ArticleId IdType="pubmed">36853250</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauder L, Kandzari DE, L&#xfc;scher TF, Mahfoud F. Renal denervation in the management of hypertension. <i>EuroIntervention</i>. 2024;20:E467-E478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11017226</ArticleId><ArticleId IdType="pubmed">38629418</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauder L, Kandzari DE, L&#xfc;scher TF, Mahfoud F. Renal denervation in the management of hypertension. EuroIntervention. 2024;20:E467&#x2013;E478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11017226</ArticleId><ArticleId IdType="pubmed">38629418</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter E. The FDA approved 2 renal denervation devices. There are still questions about who will benefit. MedTech Dive. 13 Dec 2023. Disponible en:https://www.medtechdive.com/news/renal-denervation-recor-medtronic-evidence/702385/. Consultado 20 Dic 2024.</Citation></Reference><Reference><Citation>Reuter E. The FDA approved 2 renal denervation devices. There are still questions about who will benefit. MedTech Dive. Dec 13, 2023.  [Consultado 20 Dic 2024].  Disponible en:  https://www.medtechdive.com/news/renal-denervation-recor-medtronic-evidence/702385/</Citation></Reference><Reference><Citation>Kario K, Yokoi Y, Okamura K, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension:the randomized, controlled REQUIRE trial. <i>Hypertens Res</i>. 2022;45:221-231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8766280</ArticleId><ArticleId IdType="pubmed">34654905</ArticleId></ArticleIdList></Reference><Reference><Citation>Kario K, Yokoi Y, Okamura K, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension:the randomized, controlled REQUIRE trial. Hypertens Res. 2022;45:221&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8766280</ArticleId><ArticleId IdType="pubmed">34654905</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane;2023. Avalilable at:https://training.cochrane.org/handbook. Consultado 1 Dic 2024.</Citation></Reference><Reference><Citation>Higgins JPT, Thomas J, Chandler J, et al.  Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023) Cochrane. 2023.  [Consultado 1 Dic 2024].  Avalilable at:  https://training.cochrane.org/handbook.</Citation></Reference><Reference><Citation>Sterne JAC, Savovic&#xb4;J, Page MJ, et al. RoB 2:a revised tool for assessing risk of bias in randomised trials. <i>BMJ</i>. 2019;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, Savovic&#xb4; J, Page MJ, et al. RoB 2:a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366</Citation><ArticleIdList><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson DB. Practical meta-analysis effect size calculator (Version 2023.11.27). 2023. Disponible en:https://www.campbellcollaboration.org/calculator/d-ordinal-freq. Consultado 20 Dic 2024.</Citation></Reference><Reference><Citation>Wilson DB. Practical meta-analysis effect size calculator (Version 2023.11.27) 2023.  [Consultado 20 Dic 2024].  Disponible en:  https://www.campbellcollaboration.org/calculator/ d-ordinal-freq.</Citation></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. <i>Control Clin Trials</i>. 1986;7:177-188.</Citation><ArticleIdList><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizi M, Schmieder RE, Mahfoud F, et al. Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. <i>Circulation</i>. 2019;139:2542-2553.</Citation><ArticleIdList><ArticleId IdType="pubmed">30880441</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizi M, Schmieder RE, Mahfoud F, et al. Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. Circulation. 2019;139:2542&#x2013;2553.</Citation><ArticleIdList><ArticleId IdType="pubmed">30880441</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizi M, Mahfoud F, Weber MA, et al. Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation:Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial. <i>JAMA Cardiol</i>. 2022;7:1244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9647563</ArticleId><ArticleId IdType="pubmed">36350593</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizi M, Mahfoud F, Weber MA, et al. Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation:Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial. JAMA Cardiol. 2022;7:1244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9647563</ArticleId><ArticleId IdType="pubmed">36350593</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauri L, Kario K, Basile J, et al. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation:The RADIANCE-HTN and REQUIRE clinical study designs. <i>Am Heart J</i>. 2018;195:115-129.</Citation><ArticleIdList><ArticleId IdType="pubmed">29224639</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauri L, Kario K, Basile J, et al. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation:The RADIANCE-HTN and REQUIRE clinical study designs. Am Heart J. 2018;195:115&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">29224639</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. <i>BMJ.</i> 2011;343:d400.</Citation><ArticleIdList><ArticleId IdType="pubmed">21784880</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.</Citation><ArticleIdList><ArticleId IdType="pubmed">21784880</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein M, De Marchena E. Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the &#x201c;end of the road&#x201c;for renal denervation? <i>J Am Soc Hypertens.</i> 2015;9:140-149.</Citation><ArticleIdList><ArticleId IdType="pubmed">25649995</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein M, De Marchena E. Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the &#x201c;end of the road&#x2013;for renal denervation? J Am Soc Hypertens. 2015;9:140&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">25649995</ArticleId></ArticleIdList></Reference><Reference><Citation>Haribabu S, Sharif F, Zafar H. Recent trends in renal denervation devices for resistant hypertension treatment. <i>Ir J Med Sci</i>. 2021;190:971-979.</Citation><ArticleIdList><ArticleId IdType="pubmed">33111251</ArticleId></ArticleIdList></Reference><Reference><Citation>Haribabu S, Sharif F, Zafar H. Recent trends in renal denervation devices for resistant hypertension treatment. Ir J Med Sci. 2021;190:971&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">33111251</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy CP, Natarajan P. Systolic Blood Pressure and Cardiovascular Risk:Straightening the Evidence. <i>Hypertension</i>. 2023;80:577-579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9942105</ArticleId><ArticleId IdType="pubmed">36791225</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy CP, Natarajan P. Systolic Blood Pressure and Cardiovascular Risk:Straightening the Evidence. Hypertension. 2023;80:577&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9942105</ArticleId><ArticleId IdType="pubmed">36791225</ArticleId></ArticleIdList></Reference><Reference><Citation>Kario K, Kanegae H, Okawara Y, Tomitani N, Hoshide S. Home Blood Pressure Variability Risk Prediction Score for Cardiovascular Disease Using Data From the J-HOP Study. <i>Hypertension</i>. 2024;81:2173-2180.</Citation><ArticleIdList><ArticleId IdType="pubmed">39136129</ArticleId></ArticleIdList></Reference><Reference><Citation>Kario K, Kanegae H, Okawara Y, Tomitani N, Hoshide S. Home Blood Pressure Variability Risk Prediction Score for Cardiovascular Disease Using Data From the J-HOP Study. Hypertension. 2024;81:2173&#x2013;2180.</Citation><ArticleIdList><ArticleId IdType="pubmed">39136129</ArticleId></ArticleIdList></Reference><Reference><Citation>Rader F, Kirtane AJ, Wang Y, et al. Durability of blood pressure reduction after ultrasound renal denervation:three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial. <i>EuroIntervention</i>. 2022;18:E677-E685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10241283</ArticleId><ArticleId IdType="pubmed">35913759</ArticleId></ArticleIdList></Reference><Reference><Citation>Rader F, Kirtane AJ, Wang Y, et al. Durability of blood pressure reduction after ultrasound renal denervation:three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial. EuroIntervention. 2022;18:E677&#x2013;E685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10241283</ArticleId><ArticleId IdType="pubmed">35913759</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Grosse SD, Schooley MW. Conducting Research on the Economics of Hypertension to Improve Cardiovascular Health. <i>Am J Prev Med</i>. 2017;53(6 Suppl 2):S115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5808538</ArticleId><ArticleId IdType="pubmed">29153111</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Grosse SD, Schooley MW. Conducting Research on the Economics of Hypertension to Improve Cardiovascular Health. Am J Prev Med. 2017;53(6 Suppl 2):S115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5808538</ArticleId><ArticleId IdType="pubmed">29153111</ArticleId></ArticleIdList></Reference><Reference><Citation>Kario K, Okura A, Hoshide S, Mogi M. The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. <i>Hypertens Res. 2024 47:5</i>. 2024;47:1099-1102.</Citation><ArticleIdList><ArticleId IdType="pubmed">38443614</ArticleId></ArticleIdList></Reference><Reference><Citation>Kario K, Okura A, Hoshide S, Mogi M. The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertens Res. 2024 47:5. 2024;47:1099&#x2013;1102.</Citation><ArticleIdList><ArticleId IdType="pubmed">38443614</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, He S, Pollack LM, et al. Hypertension-Associated Expenditures Among Privately Insured US Adults in 2021. <i>Hypertension</i>. 2024;81:2318-2328.</Citation><ArticleIdList><ArticleId IdType="pubmed">39253807</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, He S, Pollack LM, et al. Hypertension-Associated Expenditures Among Privately Insured US Adults in 2021. Hypertension. 2024;81:2318&#x2013;2328.</Citation><ArticleIdList><ArticleId IdType="pubmed">39253807</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor RS, Bentley A, Metcalfe K, et al. Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension. <i>Pharmacoecon Open</i>. 2024;8:525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11252101</ArticleId><ArticleId IdType="pubmed">38289517</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor RS, Bentley A, Metcalfe K, et al. Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension. Pharmacoecon Open. 2024;8:525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11252101</ArticleId><ArticleId IdType="pubmed">38289517</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Leor O, M. Ryschon A, N. Cao K, et al. Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Spain. <i>REC Interv Cardiol.</i> 2024;6:305-312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12097359</ArticleId><ArticleId IdType="pubmed">40417339</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Leor O, M, Ryschon A, N, Cao K, et al. Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Spain. REC Interv Cardiol. 2024;6:305&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12097359</ArticleId><ArticleId IdType="pubmed">40417339</ArticleId></ArticleIdList></Reference><Reference><Citation>M Zeijen VJ, V&#xf6;lz S, Zeller T, et al. Long-term safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension:8-year results from the ACHIEVE study. <i>Clin Res Cardiol.</i>https://doi.org/10.1007/s00392-024-02555-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">39441345</ArticleId></ArticleIdList></Reference><Reference><Citation>M Zeijen VJ, V&#xf6;lz S, Zeller T, et al. Long-term safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension:8-year results from the ACHIEVE study. Clin Res Cardiol. 2024 https://doi.org/ 10.1007/s00392-024-02555-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">39441345</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizi M, Daemen J, Lobo MD, et al. 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. <i>JACC Cardiovasc Interv</i>. 2020;13:2922-2933.</Citation><ArticleIdList><ArticleId IdType="pubmed">33357531</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizi M, Daemen J, Lobo MD, et al. 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. JACC Cardiovasc Interv. 2020;13:2922&#x2013;2933.</Citation><ArticleIdList><ArticleId IdType="pubmed">33357531</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamrahian SM, Maarouf OH, F&#xfc;l&#xf6;p T. A Critical Review of Medication Adherence in Hypertension:Barriers and Facilitators Clinicians Should Consider. <i>Patient Prefer Adherence</i>. 2022;16:2749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552797</ArticleId><ArticleId IdType="pubmed">36237983</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamrahian SM, Maarouf OH, F&#xfc;l&#xf6;p T. A Critical Review of Medication Adherence in Hypertension:Barriers and Facilitators Clinicians Should Consider. Patient Prefer Adherence. 2022;16:2749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552797</ArticleId><ArticleId IdType="pubmed">36237983</ArticleId></ArticleIdList></Reference><Reference><Citation>Borenstein M. How to understand and report heterogeneity in a meta-analysis:The difference between I-squared and prediction intervals. <i>Integr Med Res</i>. 2023;12:101014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11208730</ArticleId><ArticleId IdType="pubmed">38938910</ArticleId></ArticleIdList></Reference><Reference><Citation>Borenstein M. How to understand and report heterogeneity in a meta-analysis:The difference between I-squared and prediction intervals. Integr Med Res. 2023;12:101014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11208730</ArticleId><ArticleId IdType="pubmed">38938910</ArticleId></ArticleIdList></Reference><Reference><Citation>Kario K, Kai H, Nanto S, Yokoi H. Anti-hypertensive medication adherence in the REQUIRE trial:post-hoc exploratory evaluation. <i>Hypertens Res</i>. 2023;46:2044-2047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10404509</ArticleId><ArticleId IdType="pubmed">37264122</ArticleId></ArticleIdList></Reference><Reference><Citation>Kario K, Kai H, Nanto S, Yokoi H. Anti-hypertensive medication adherence in the REQUIRE trial:post-hoc exploratory evaluation. Hypertens Res. 2023;46:2044&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10404509</ArticleId><ArticleId IdType="pubmed">37264122</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahfoud F, Azizi M, Ewen S, et al. Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies. <i>Eur Heart J</i>. 2020;41:1588-1599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7174031</ArticleId><ArticleId IdType="pubmed">32211888</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahfoud F, Azizi M, Ewen S, et al. Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies. Eur Heart J. 2020;41:1588&#x2013;1599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7174031</ArticleId><ArticleId IdType="pubmed">32211888</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandzari DE, Mahfoud F, Weber MA, et al. Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension:A Consensus Document From the Hypertension Academic Research Consortium. <i>Circulation</i>. 2022;145:847-863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8912966</ArticleId><ArticleId IdType="pubmed">35286164</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandzari DE, Mahfoud F, Weber MA, et al. Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension:A Consensus Document From the Hypertension Academic Research Consortium. Circulation. 2022;145:847&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8912966</ArticleId><ArticleId IdType="pubmed">35286164</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandzari DE, Mahfoud F, Bhatt DL, et al. Confounding Factors in Renal Denervation Trials:Revisiting Old and Identifying New Challenges in Trial Design of Device Therapies for Hypertension. <i>Hypertension</i>. 2020;76:1410-1417.</Citation><ArticleIdList><ArticleId IdType="pubmed">32981360</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandzari DE, Mahfoud F, Bhatt DL, et al. Confounding Factors in Renal Denervation Trials:Revisiting Old and Identifying New Challenges in Trial Design of Device Therapies for Hypertension. Hypertension. 2020;76:1410&#x2013;1417.</Citation><ArticleIdList><ArticleId IdType="pubmed">32981360</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>